| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Aug 2025 | 5 Aug 2025 |
| Shilpa Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve unaudited financial results of the company for the quarter ended June 30 2025 outcome (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 26 May 2025 | 19 May 2025 |
| Pursuant to the provisions of Regulation 29 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby wish to inform you that the Meeting of the Board of Directors of Shilpa Medicare Limited is scheduled on Monday, 26 May 2025 inter alia to consider and approve the following: (a) audited financial statements (Consolidated & Standalone) for the financial year ending March 31, 2025 (b) audited financial results (Consolidated & Standalone) for the quarter and financial year ending March 31, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (c ) recommendation of dividend, if any for the Financial Year 2024-25. BM outcome (As Per BSE Announcement Dated on: 26/05/2025) | ||
| Board Meeting | 10 Feb 2025 | 3 Feb 2025 |
| SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve The Meeting of Board of Directors of the Company will be held on Monday 10 February 2025 to inter alia consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31 December 2024. In terms of the Code of Conduct for Prevention of Insider Trading in Securities of the Company the Trading Window has been closed with effect from 1 January 2025 and remains closed upto 48 hours after the declaration of Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31 December 2024 BM outcome Integrated filing (As Per BSE Announcement Dated on 10/02/2025) | ||
| Board Meeting | 13 Nov 2024 | 4 Nov 2024 |
| SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30 September 2024 Considered and approved 1.The Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2024. A copy of Un-Audited Financial Result along with the Limited Review report is enclosed as Annexure 1. 2.Inducted Dr. Anita Bandyopadhyay, Non-Executive Independent Director as a member of Audit Committee. (As Per BSE Announcement dated on 13.11.2024) | ||
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
Shilpa Medicare is the first Indian company to gain approval for Phase III trials of Recombinant Human Albumin.
The European Directorate for the Quality of Medicines & Healthcare (EDQM) gave Shilpa Pharma Lifesciences, the company's subsidiary, the Certificate of Suitability (CEP) for Nifedipine.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
